Pelvic Fractures in Polytraumatized Patients With Hemodynamic Instability: Angioembolization vs Preperitoneal Packing

January 4, 2022 updated by: Nuria Llorach-Perucho

Randomized Multicenter Study on the Management of Pelvic Fractures in Polytraumatized Patients With Hemodynamic Instability: Angioembolization vs Preperitoneal Packing

Pelvic fracture is a usual injury in trauma patients. An unstable trauma patient with a pelvic fracture has an elevated risk of death due to pelvic bleeding and the associated injuries. Traditionally, it has been estimated that the main source of bleeding is venous and, consequently, the main treatment has been the preperitoneal pelvic packing. Nevertheless, according to new data, arterial bleeding appears to be a more important source of pelvic bleeding than it was thought and angioembolization seems to be a good alternative in the treatment of these injuries. Consequently, it is important to define better the management of these patients.

This investigation project consists in a clinical trial study, performed by a multidisciplinary team of many hospitals around the country, in which angioembolization and preperitoneal pelvic packing are compared. Unstable trauma patients with a pelvic fracture and no other injuries (negative FAST / peritoneal aspiration, no evidence of bone fractures or thoracic injuries) will be submitted, in less than 60 minutes from hospital arrival, to angioembolization or preperitoneal pelvic packing, according to randomization. There will be a specific timing evaluation of different markers: hemodynamic (vital signs at arrival, immediately and 24 hours after treatment) and analytic (at arrival and upon entering to the Intensive Care Unit). Registered variables include: blood cell transfusions, vasoactive drug requirements, time elapsed between hospital admission and intervention, treatment duration, need of other strategies to stop pelvic bleeding, complications and mortality.

The objective of this study is to determinate if angioembolization is superior to preperitoneal pelvic packing for pelvic bleeding control in unstable trauma patients due to pelvic bleeding.

Study Overview

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Barcelona
      • Sabadell, Barcelona, Spain, 08208
        • Corporacio Sanitaria Parc Tauli

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Systolic blood pressure ≤ 90 mmHg
  • Heart rate > 100 bpm
  • Shock Index ≥ 0,8
  • Pelvic fracture
  • Negative FAST / peritoneal aspiration

Exclusion Criteria:

  • Other causes of bleeding that require treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Angioembolization

Via the femoral route, a non-selective pelvic arteriography with a selective embolization of the arterial branches that show direct or indirect signs of injury will be performed.

In the event of persistent hemodynamic instability after selective embolization, non-selective bilateral embolization of the internal iliac arteries will be evaluated.

The material used will vary depending on the characteristics of the injury and the availability of the materials.

ACTIVE_COMPARATOR: Preperitoneal Pelvic Packing

Pfannestiel incision / infraumbilical laparotomy. Dissection of tissues up to and including the transversalis fascia. Inferior to this and anterior to the peritoneum, the preperitoneal cavity is identified.

Inclusion of radiopaque laparotomy gauze in each hemipelvis, from the posterior part (anterior to the sacro-iliac joint) to the most anterior in the retropubic position. Subsequently, the closure is carried out to increase the plugging effect.

A second intervention is required to remove the material in 24-48 hours.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pelvic bleeding control based on clinical response
Time Frame: 24 hours
Clinical response after the intervention
24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Additional techniques
Time Frame: Through study completion, an average of 2 years
Need for additional techniques after the intervention to control bleeding associated with pelvic fracture
Through study completion, an average of 2 years
Post-procedure complications
Time Frame: Through study completion, an average of 2 years
Presence of post-procedure complications
Through study completion, an average of 2 years
Post-procedure complications degree
Time Frame: Through study completion, an average of 2 years
Description of post-procedure complications: Clavien Dindo scale
Through study completion, an average of 2 years
Post-procedure complications degree
Time Frame: Through study completion, an average of 2 years
Description of post-procedure complications: Comprehensive Complication Index
Through study completion, an average of 2 years
Mortality
Time Frame: Through study completion, an average of 2 years
Death of the pacient (cause and date)
Through study completion, an average of 2 years
Blood cell transfusion
Time Frame: Through study completion, an average of 2 years
Need for blood cell transfusion for patients (number and need for masive transfusion protocol activation)
Through study completion, an average of 2 years
Time until intervention
Time Frame: Time until intervention (up to 60 minutes)
Time elapsed between hospital admission and intervention
Time until intervention (up to 60 minutes)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time until arrival at hospital
Time Frame: Time until arrival at hospital (up to 30 minutes)
Time elapsed between prehospital attention and hospital admission
Time until arrival at hospital (up to 30 minutes)
Duration of angioembolization
Time Frame: Through study completion, an average of 2 years
Duration of angioembolization
Through study completion, an average of 2 years
Angioembolization treatment
Time Frame: Through study completion, an average of 2 years
Arteries treated with angioembolization
Through study completion, an average of 2 years
Duration of Preperitoneal Pelvic Packing
Time Frame: Through study completion, an average of 2 years
Duration of Preperitoneal Pelvic Packing
Through study completion, an average of 2 years
Intensive care unit stay
Time Frame: Through study completion, an average of 2 years
Number of days that the patient remains in the intensive care unit
Through study completion, an average of 2 years
Hospital stay
Time Frame: Through study completion, an average of 2 years
Number of days that the patient remains in hospital
Through study completion, an average of 2 years
Readmission
Time Frame: 30 days after discharge
Readmission 30 days after discharge
30 days after discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Study Director: Andrea Campos-Serra, MD, Corporacion Parc Tauli

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 1, 2022

Primary Completion (ACTUAL)

January 1, 2022

Study Completion (ACTUAL)

January 1, 2022

Study Registration Dates

First Submitted

February 16, 2021

First Submitted That Met QC Criteria

February 18, 2021

First Posted (ACTUAL)

February 21, 2021

Study Record Updates

Last Update Posted (ACTUAL)

January 19, 2022

Last Update Submitted That Met QC Criteria

January 4, 2022

Last Verified

January 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Trauma

Clinical Trials on Angioembolization

3
Subscribe